These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34082218)

  • 1. Non-superiority of zuranolone (SAGE-217) at the longer-term.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2021 Aug; 291():329-330. PubMed ID: 34082218
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
    Bullock A; Gunduz-Bruce H; Zammit GK; Qin M; Li H; Sankoh AJ; Silber C; Kanes SJ; Jonas J; Doherty J
    Hum Psychopharmacol; 2022 Jan; 37(1):e2806. PubMed ID: 34352138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zuranolone: First Approval.
    Heo YA
    Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
    Arnaud A; Bonthapally V
    J Affect Disord; 2022 Mar; 301():445-447. PubMed ID: 35032505
    [No Abstract]   [Full Text] [Related]  

  • 5. Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2022 Sep; 313():149-150. PubMed ID: 35780962
    [No Abstract]   [Full Text] [Related]  

  • 6. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
    Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
    J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New depression drug zuranolone one step closer to FDA ruling.
    Carvalho T
    Nat Med; 2023 May; 29(5):1032-1033. PubMed ID: 37041352
    [No Abstract]   [Full Text] [Related]  

  • 8. Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?
    Pine DS
    Am J Psychiatry; 2023 Sep; 180(9):631-633. PubMed ID: 37654113
    [No Abstract]   [Full Text] [Related]  

  • 9. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
    Bullock A; Kaul I; Li S; Silber C; Doherty J; Kanes SJ
    J Neurol Sci; 2021 Feb; 421():117277. PubMed ID: 33387701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concerns That May Limit the Utility of Zuranolone.
    Prasad V; Allely D
    JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAGE-217, A Novel GABA
    Hoffmann E; Nomikos GG; Kaul I; Raines S; Wald J; Bullock A; Sankoh AJ; Doherty J; Kanes SJ; Colquhoun H
    Clin Pharmacokinet; 2020 Jan; 59(1):111-120. PubMed ID: 31338688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of SAGE-217 in Patients with Major Depressive Disorder.
    Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
    N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Oral Drug Rapidly Treats Postpartum Depression.
    Slomski A
    JAMA; 2021 Sep; 326(9):800. PubMed ID: 34547091
    [No Abstract]   [Full Text] [Related]  

  • 16. Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection.
    Portmann GA; Simmons DM
    J Pharm Biomed Anal; 1995 Aug; 13(9):1189-93. PubMed ID: 8573648
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of C19-, C21-, C24-, and C27-3-oxosteroids by rat-liver microsomes.
    Björkhem I; Danielsson H; Wikvall K
    Eur J Biochem; 1973 Jul; 36(1):8-15. PubMed ID: 4147367
    [No Abstract]   [Full Text] [Related]  

  • 18. Heterocyclic corticosteroids. I. Biological properties of the 6,16 -dimethyl-4,6-pregnadiene-11 ,17,21-triol-20-one(3,2c)-2'-phenylpyrazole-21-acetate and its 21-desoxy derivative.
    Steelman SL; Morgan ER; Glitzer MS
    Steroids; 1971 Aug; 18(2):129-39. PubMed ID: 5126815
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of a series of C(21)O(2) pregnanes from fecal extracts of a pregnant black rhinoceros (Diceros bicornis minor).
    Lance VA; Patton ML; Hagey LR
    Steroids; 2001 Dec; 66(12):875-81. PubMed ID: 11711115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anesthetic pregnanes counteract androgen-induced defeminization.
    Gonzalez-Mariscal G; Fernandez-Guasti A; Beyer C
    Neuroendocrinology; 1982; 34(5):357-62. PubMed ID: 7078704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.